A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

About

Brief Summary

The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.

Primary Purpose

Treatment

Study Type

Interventional

Phase

Phase 3

Eligibility

Gender

All

Healthy Volunteers

No

Minimum Age

N/A

Maximum Age

N/A

Inclusion Criteria:

Participants with FA who completed and directly rolled over from a previous vatiquinone clinical study.
Males and females of childbearing potential must be willing to use an effective method of contraception (for example, implants, injectables, transdermal patches, combined oral contraceptives, barrier methods, and intrauterine devices) from the time consent is signed until 30 days after the last dose of study drug or Early Termination Visit.